Could a cholesterol shot stop a first heart attack?
NCT ID NCT07734753
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This study looks at whether alirocumab, a drug that lowers cholesterol, can reduce the risk of heart attack, stroke, or death in people who have hardened arteries but have never had a heart attack or stroke before. Researchers will analyze data from routine medical care to compare those who take alirocumab with those who do not. The goal is to see if starting this treatment earlier could prevent a first major cardiovascular event.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Alirocumab, a PCSK9 inhibitor drug that lowers cholesterol
- What this could lead to
- If alirocumab proves effective, it could support using this cholesterol-lowering drug earlier in people with artery disease who have not yet had a heart attack or stroke.
- What could go wrong
- This is an observational analysis of existing medical records, not a controlled experiment, so results may be influenced by unmeasured differences between groups. The drug also requires regular injections and can cause injection-site reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITHOUT PRIOR ISCHEMIC EVENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sanofi
Amsterdam, 1105 BP, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.